ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 336

The Additive Inflammatory in Vivo and in Vitro Effects of Thymic Stromal Lymphopoietin (TSLP) and IL-7 in Arthritis Underscore the Therapeutic Rationale for blockade of Their Common Receptor Subunit

M.R. Hillen1,2, S.A.Y. Hartgring1,2, T.R.D.J. Radstake2,3, C.E. Hack1,2, F.P.J.G. Lafeber1 and J.a.G. van Roon1,2, 1Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, 2Laboratory for Translational Immunology, UMC Utrecht, Utrecht, Netherlands, 3Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Animal models, Dendritic cells, rheumatoid arthritis (RA) and rheumatoid arthritis, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose

Interleukin (IL)-7 and thymic stromal lymphopoietin (TSLP) are cytokines that signal through the IL-7Ra subunit and play proinflammatory roles in experimental arthritis and rheumatoid arthritis (RA). IL-7R blockade can potentially block signalling of both cytokines. In this study the potential of IL-7R and TSLPR signalling inhibition as well as simultaneous inhibition was investigated in murine experimental arthritis. In addition, the additive effects of IL-7 and TSLP in human RA in vitro dendritic cell (DC)/T-cell co-cultures were studied.

Methods

Proteoglycan-induced arthritis was induced in wildtype mice (WT) and mice deficient for the TSLP receptor subunit (TSLPR) and mice of both genotypes were treated with anti-IL-7R or PBS. Arthritis severity was assessed and paw lysate and serum were collected for cytokine analyses. CD1c DCs and CD4 T-cells were isolated from blood of RA patients and were co-cultured in presence of IL-7, TSLP or the combination of both cytokines and proliferation and cytokine production were assessed.

Results

Arthritis severity and synovitis were significantly decreased in TSLPR-/- mice treated with anti-IL-7R compared to control mice (Arthritis severity; mean area under the curve ± SEM: 25 ± 5.9 vs. 50.7 ± 6.9; p<0.01). This was associated with strongly reduced radiographic joint damage and osteoclast activity, which were significantly lower in TSLPR-/- mice treated with anti-IL-7R compared to WT mice treated with anti-IL-7R, PBS treated TSLPR-/- mice or PBS treated WT mice (Radiographic joint damage: Mean score ± SEM: 0.1 ± 0.1, 0.6 ± 0.1, 0.3 ± 0.1, 1.4 ± 0.2 respectively; all p<0.001). This was associated with  decreased levels of IL-17, IL-6, IL-1β and CD40L, which were all robustly downregulated by combined blockade of IL-7 and TSLP signalling (all p<0.05). In DC/CD4 T-cell co-cultures from RA patients, TSLP and IL-7 additively increased T-cell proliferation (p<0.01) and production of Th17-associated cytokines (IL-17, IL-22, IL-6; all p<0.05) and T-cell attracting chemokines (all p<0.05).

Conclusion

TSLP and IL-7 additively promote production of Th17-specific and Th17-associated cytokines, linked with enhanced inflammation and immunopathology. As both cytokines signal via the IL-7Ra, these data emphasize the need for drugs that target this subunit to abrogate activity of both ligands and prevent immunopathology in RA.


Disclosure:

M. R. Hillen,
None;

S. A. Y. Hartgring,
None;

T. R. D. J. Radstake,
None;

C. E. Hack,
None;

F. P. J. G. Lafeber,
None;

J. A. G. van Roon,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-additive-inflammatory-in-vivo-and-in-vitro-effects-of-thymic-stromal-lymphopoietin-tslp-and-il-7-in-arthritis-underscore-the-therapeutic-rationale-for-blockade-of-their-common-receptor-subu/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology